Zobrazeno 1 - 10
of 663
pro vyhledávání: '"Ian R, White"'
An evaluation of sample size requirements for developing risk prediction models with binary outcomes
Publikováno v:
BMC Medical Research Methodology, Vol 24, Iss 1, Pp 1-13 (2024)
Abstract Background Risk prediction models are routinely used to assist in clinical decision making. A small sample size for model development can compromise model performance when the model is applied to new patients. For binary outcomes, the calibr
Externí odkaz:
https://doaj.org/article/c43b964e281a424e812fb03319c1dcda
Autor:
Carole Lunny, Areti-angeliki Veroniki, Julian P. T. Higgins, Sofia Dias, Brian Hutton, James M. Wright, Ian R. White, Penny Whiting, Andrea C. Tricco
Publikováno v:
Systematic Reviews, Vol 13, Iss 1, Pp 1-23 (2024)
Abstract Introduction Network meta-analyses (NMAs) have gained popularity and grown in number due to their ability to provide estimates of the comparative effectiveness of multiple treatments for the same condition. The aim of this study is to conduc
Externí odkaz:
https://doaj.org/article/03615f7725a941eabd486f4725d1d95e
Publikováno v:
Trials, Vol 24, Iss 1, Pp 1-13 (2023)
Abstract Background Overall survival is the “gold standard” endpoint in cancer clinical trials. It plays a key role in determining the clinical- and cost-effectiveness of a new intervention and whether it is recommended for use in standard of car
Externí odkaz:
https://doaj.org/article/feb1a8274067465395fbf5561ed28cdd
Publikováno v:
BMC Medical Research Methodology, Vol 23, Iss 1, Pp 1-19 (2023)
Abstract Background For certain conditions, treatments aim to lessen deterioration over time. A trial outcome could be change in a continuous measure, analysed using a random slopes model with a different slope in each treatment group. A sample size
Externí odkaz:
https://doaj.org/article/4fe16e135a4b4d24bdb06c7b2cf67e40
Publikováno v:
Trials, Vol 24, Iss 1, Pp 1-12 (2023)
Abstract Background In a non-inferiority trial, the choice of margin depends on the expected control event risk. If the true risk differs from expected, power and interpretability of results can be affected. A non-inferiority frontier pre-specifies a
Externí odkaz:
https://doaj.org/article/24d9b240f70b49c48aa81289fe4135d7
Autor:
Richard A. Parker, Christopher J. Weir, Tra My Pham, Ian R. White, Nigel Stallard, Mahesh K. B. Parmar, Robert J. Swingler, Rachel S. Dakin, Suvankar Pal, Siddharthan Chandran
Publikováno v:
Trials, Vol 24, Iss 1, Pp 1-15 (2023)
Abstract Background MND-SMART is a platform, multi-arm, multi-stage, multi-centre, randomised controlled trial recruiting people with motor neuron disease. Initially, the treatments memantine and trazodone will each be compared against placebo, but o
Externí odkaz:
https://doaj.org/article/79ee44339d2044749471abb674bbc6f1
Publikováno v:
Systematic Reviews, Vol 11, Iss 1, Pp 1-11 (2022)
Abstract Background Research overlap and duplication is a recognised problem in the context of both pairwise and network systematic reviews and meta-analyses. As a case study, we carried out a scoping review to identify and examine duplicated network
Externí odkaz:
https://doaj.org/article/46fc8f5fe8654cbab993d647ae66542a
Publikováno v:
Trials, Vol 23, Iss 1, Pp 1-17 (2022)
Abstract Background It has long been advised to account for baseline covariates in the analysis of confirmatory randomised trials, with the main statistical justifications being that this increases power and, when a randomisation scheme balanced cova
Externí odkaz:
https://doaj.org/article/57219ce60f6f4632934636daa4019bb5
Publikováno v:
BMC Medical Research Methodology, Vol 22, Iss 1, Pp 1-14 (2022)
Abstract Background Systematic reviews and meta-analysis of time-to-event outcomes are frequently published within the Cochrane Database of Systematic Reviews (CDSR). However, these outcomes are handled differently across meta-analyses. They can be a
Externí odkaz:
https://doaj.org/article/78639211b7af4d7397565ed7ceb4d2ad
Autor:
Rebecca M. Turner, Anna Turkova, Cecilia L. Moore, Alasdair Bamford, Moherndran Archary, Linda N. Barlow-Mosha, Mark F. Cotton, Tim R. Cressey, Elizabeth Kaudha, Abbas Lugemwa, Hermione Lyall, Hilda A. Mujuru, Veronica Mulenga, Victor Musiime, Pablo Rojo, Gareth Tudor-Williams, Steven B. Welch, Diana M. Gibb, Deborah Ford, Ian R. White, and the ODYSSEY Trial Team
Publikováno v:
BMC Medical Research Methodology, Vol 22, Iss 1, Pp 1-11 (2022)
Abstract Background Clinical trial investigators may need to evaluate treatment effects in a specific subgroup (or subgroups) of participants in addition to reporting results of the entire study population. Such subgroups lack power to detect a treat
Externí odkaz:
https://doaj.org/article/4630e04e33764bccb00fb99114b172c4